Search PubMed⌕ Search

PubMed · 2669064

[Syndrome X].

Abstract

The authors reviewed the literature on X syndrome, finding criteria of inclusion/exclusion so different as to often invalidate the results. The syndrome should be diagnosed only in patients with typical anginal pain on effort relieved by nitroglycerin or rest, with perfectly regular coronary vessels and a normal resting left ventricle, without any evidence of variant angina. Other diseases must be strictly excluded (mostly at the esophageal level) and an ischemic process has to be proved by means of more than one provocative test. Interesting pathophysiological findings are the dynamic limitation of coronary flow reserve and frequent reports of a left ventricle dysfunction during stress. Whether these last findings represent an independent entity, an aspect or stage of the variant angina or the initial appearance of a cardiomyopathy, has yet to be clarified. Frequent reports of a higher prevalence of X syndrome in women have not been substantiated and could be explained by many biases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Favaro, F Masini, M L Maffei, G Botti. 1989. [Syndrome X].. https://pubmed.ncbi.nlm.nih.gov/2669064/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

OBJECTIVE: Ischemic preconditioning is an increased tolerance to myocardial ischemia during the second of two consecutive exercise tests. ATP-sensitive K(+) channel blockers, such as glinides and sulfonylurea drugs, can induce loss of ischemic preconditioning. This study aimed to investigate the effects of repaglinide, a hypoglycemic agent with an affinity for myocardial ATP-sensitive K (+)channels, on the results of consecutive exercise tests in patients with diabetes and multivessel coronary artery disease. METHODS: Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study. The patients underwent two consecutive treadmill exercise tests (phase 1). On the day after these exercise tests, 2 mg of oral repaglinide was given to the patients. One week later, two exercise tests were repeated consecutively (phase 2). RESULTS: All patients achieved 1.0-mm ST-segment depression during the four exercise tests (T1, T2, T3, and T4). In phase 2, seven patients improved in time to onset of 1.0-mm ST-segment depression. The worsening of the time to onset of 1.0-mm ST-segment depression in phase 2 demonstrated ischemic preconditioning block in 83.3% of patients (P=0.0001). Even the postexercise electrocardiographic parameters (ST-segment depression morphology and magnitude and arrhythmias) were significantly different between the groups with and without pharmacologic ischemic preconditioning block (P=0.031). CONCLUSIONS: Repaglinide, an oral hypoglycemic agent with ATP-sensitive K(+) channel-blocker activity, eliminated the myocardial ischemic preconditioning in patients with coronary disease and diabetes.

Angina Pectoris↗